Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 6/20 | 0.40 |
| ▸ | DRD3 | P35462 | 6/20 | 0.40 |
| ▸ | DRD1 | P21728 | 4/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337644 | 0.87 | ALDH1A1 (0.40) | ALDH1A1POLBSIGMAR1 | |
| SCHEMBL2759852 | 0.87 | ALDH1A1 (0.40) | ALDH1A1POLBSIGMAR1 | |
| SCHEMBL29156269 | 0.84 | ALDH1A1 (0.56) | ALDH1A1POLBSIGMAR1DRD2DRD3 | |
| SCHEMBL29156272 | 0.84 | ALDH1A1 (0.56) | ALDH1A1POLBSIGMAR1DRD2DRD3 | |
| SCHEMBL1880066 | 0.79 | SIGMAR1 (0.47) | POLBSIGMAR1GBA1SPHK2SPHK1 | |
| SCHEMBL945183 | 0.79 | SIGMAR1 (0.47) | POLBSIGMAR1GBA1SPHK2SPHK1 | |
| SCHEMBL945182 | 0.79 | SIGMAR1 (0.47) | POLBSIGMAR1GBA1SPHK2SPHK1 | |
| SCHEMBL303965 | 0.79 | ALDH1A1 (0.35) | ALDH1A1POLBSIGMAR1 | |
| Hydrochloric Acid SCHEMBL1442190 | 0.78 | SIGMAR1 (0.46) | POLBSIGMAR1GBA1SPHK2SPHK1 | |
| Hydrochloric Acid SCHEMBL1730624 | 0.78 | SIGMAR1 (0.46) | POLBSIGMAR1GBA1SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-8093242-B2 | Crystalline forms of a pyridine derivative | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093242-B2 | Crystalline forms of a pyridine derivative | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093242-B2 | Crystalline forms of a pyridine derivative | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1928886-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SmithKline Beecham Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | ALDH1A1 337/4885POLB 2084/4885SIGMAR1 676/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | ALDH1A1 490/4885POLB 3253/4885SIGMAR1 657/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | ALDH1A1 1956/4885POLB 3030/4885SIGMAR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.